This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.
Aortic valve sclerosis (AVS) has a prevalence of 2% to 7% in the population above 65 years of age. In industrialized countries, aortic valve sclerosis is most frequently caused by progressive calcification and degeneration of the aortic cusps. Coronary artery disease (CAD) is the most significant single cause of death in the world. In developed countries, more than 25% of all deaths in persons older than 35 years are due to CAD. More than half of acute myocardial infarctions occur without previous history or symptoms of CAD. In recent years, there has been a special emphasis on lipoprotein(a) (Lp(a)), a significant, causal, and nonmodifiable predictor of valvular outcomes and CAD in the general population
Study Type
OBSERVATIONAL
Enrollment
100
A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.
Sohag University
Sohag, Egypt
Incidence of significance of coronary lesions
Incidence of significance of coronary lesions in relation to lipoprotein (a) level was recorded.
Time frame: 1 month post-procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.